TRPC6 is a Biomarker for Prognosis and Immunotherapy of Stomach Adenocarcinoma Based on Bioinformatic Analysis and Experimental Validation
Xingchi Hu, Hongwei Wang, Haitao Sun, Jingxin Zhang, ZhenXiong Ye, Zhenhua Huang · 2024
Read TRPC6 is a Biomarker for Prognosis and Immunotherapy of Stomach Adenocarcinoma Based on Bioinformatic Analysis and Experimental Validation by Xingchi Hu, Hongwei Wang, Haitao Sun, Jingxin Zhang, ZhenXiong Ye, Zhenhua Huang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11649498.txt.
Description
Xingchi Hu and co-authors study TRPC6 as a biomarker for prognosis and immunotherapy in stomach adenocarcinoma. Their paper uses data analysis with lab checks.
TRPC6 is a key member of the transient receptor potential channel family, active in many normal states and diseases. Past work linked it to stomach cancer growth, but its exact role was unclear. Using gene and clinical data from a cancer atlas, the team gauged its expression and outlook value with survival analysis. Immune cell entry and checkpoint gene levels were also checked. Drug response tests probed links to treatments. Lab tests then checked the data findings.
Catalog record
| CREATOR | Xingchi Hu, Hongwei Wang, Haitao Sun, Jingxin Zhang, ZhenXiong Ye, Zhenhua Huang |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |